Fig. 7: HYP sensitizes HCC cells to both sorafenib and regorafenib treatment in the hydrodynamic transfection-induced liver cancer model. | Cell Death & Disease

Fig. 7: HYP sensitizes HCC cells to both sorafenib and regorafenib treatment in the hydrodynamic transfection-induced liver cancer model.

From: Targeting USP18 overcomes acquired resistance in hepatocellular carcinoma by regulating NCOA4 deISGylation and ferroptosis

Fig. 7

A Schematic diagram of the treatment regimen with sorafenib (Sora) or HYP, or the combination of sorafenib (Sora) and HYP. B, C The tumor numbers in the livers (B) and the liver weight to body weight ratios (C) from mice in the indicated groups (means ± SEM, *p < 0.05, **p < 0.01 versus Vehicle group, #p < 0.05, ##p < 0.01, and ###p < 0.001 versus sorafenib (Sora) group, one-way ANOVA test). D Representative images of liver tumors, H&E staining images, and IHC images of Ki67 in the indicated groups. n = 6 mice per group. Scale bars in the morphology, 5 mm. Scale bars in H&E, 2.5 mm. Scale bars in Ki67, 50 μm. E Schematic diagram of the treatment regimen with regorafenib (Reg) alone or the combination of regorafenib (Reg) and HYP. F, G The tumor numbers in the livers (F) and the liver weight to body weight ratios (G) from mice in the indicated groups (means ± SEM, *p < 0.05 versus Vehicle group, #p < 0.05 versus regorafenib (Reg) group, one-way ANOVA test). H, I Representative images of liver tumors (H), H&E staining images, and IHC images of Ki67 (I) in the indicated groups. n = 6 mice per group. Scale bars in the morphology, 5 mm (H). Scale bars in H&E, 2.5 mm. Scale bars in Ki67, 50 μm (I).

Back to article page